Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024)
Fulcrum Therapeutics (FULC) reported EBT Margin of 69.26% for Q2 2024, up 277187.0% year-over-year from N/an in Q3 2023, and up 102.44% quarter-over-quarter from 2842.25% in Q4 2023.
Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has 5 years of EBT Margin data on file, last reported at 69.26% in Q2 2024.
- EBT Margin for Q2 2024 came in at 69.26%, up 277187.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 91.52% (down 6673.0% YoY), and the FY2024 annual result was 12.16%, up 345790.0% from the prior year.
- EBT Margin advanced to 69.26% in Q2 2024 per FULC's latest filing, from 2842.25% in the prior quarter.
- Over five years, EBT Margin peaked at 69.26% in Q2 2024 and troughed at 8399.66% in Q1 2023.
- A 5-year average of 1885.27% and a median of 1026.08% in 2020 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2024: EBT Margin plunged 739935 bps in 2023, then surged 277187 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 419.41% in 2020, then decreased by 11 bps to 464.29% in 2021, then slumped by 722 bps to 3815.33% in 2022, then rose by 26 bps to 2842.25% in 2023, then soared by 102 bps to 69.26% in 2024.
- Business Quant data shows FULC's EBT Margin at 69.26% in Q2 2024, 2842.25% in Q4 2023, and 3164.3% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 69.26% |
| Dec 31, 2023 | -2,842.25% |
| Sep 30, 2023 | -3,164.30% |
| Jun 30, 2023 | -2,702.61% |
| Mar 31, 2023 | -8,399.66% |
| Dec 31, 2022 | -3,815.33% |
| Sep 30, 2022 | -2,006.59% |
| Jun 30, 2022 | -1,810.31% |
| Mar 31, 2022 | -1,000.31% |
| Dec 31, 2021 | -464.29% |
| Sep 30, 2021 | -419.78% |
| Jun 30, 2021 | -448.48% |
| Mar 31, 2021 | -354.96% |
| Dec 31, 2020 | -419.41% |
| Sep 30, 2020 | -1,026.08% |
| Jun 30, 2020 | -784.25% |
| Mar 31, 2020 | -2,460.27% |